Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2005 Aug;79(15):9854-61.
doi: 10.1128/JVI.79.15.9854-9861.2005.

Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins

Affiliations
Comparative Study

Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins

Man Ki Song et al. J Virol. 2005 Aug.

Abstract

Measles virus (MV) hemagglutinin (MV-H) and fusion (MV-F) proteins induce plaque reduction neutralizing (PRN) antibodies and cell-mediated immune responses that protect against clinical measles. DNA vaccines that encode MV-H and MV-F are being investigated as a new generation of measles vaccine to protect infants too young to receive currently licensed attenuated measles vaccines. However, it is unclear whether DNA vaccines encoding both MV-H and MV-F act synergistically to induce stronger immunity than immunization with plasmids encoding MV-H or MV-F alone. To address this question, we generated Sindbis virus-based pSINCP DNA vaccines that encode either MV-H or MV-F alone or bicistronic or fusion system vectors that encode both MV-H and MV-F (to mimic MV infection where both MV-H and MV-F proteins are expressed by the same mammalian cell). Mice immunized with DNA vaccine encoding MV-H alone developed significantly greater PRN titers than mice immunized with bicistronic constructs. Interestingly, the presence of MV-F in the bicistronic constructs stimulated serum MV-specific immunoglobulin G of reduced avidity. By contrast, mice immunized with bicistronic constructs induced equivalent or higher levels of MV-specific gamma interferon responses than mice immunized with DNA vaccine encoding MV-H alone. These data will help guide the design of DNA-based MV vaccines to be used early in life in a heterologous prime-boost strategy.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Schematic diagram of eukaryotic expression vectors. All constructs (not drawn to scale) were based on pSINCP. The pMSIN-H vector contains a full-length MV-H under the control of Sindbis virus subgenomic promoter (SubP). pMSIN-FL and pMSIN-FdU encode MV-F with or without its 5′ NTR, respectively. The bicistronic expression vectors, pMSINH-FdU and pMSINH-IRESFdU, encode MV-F under the control of SubP or the IRES element, respectively. The plasmid pMSINH-FdU(dC) contains MVF with mutations in its cleavage site (RRHKR to RRTSR at amino acids 108 to 112). The fusion construct, pMSINH-FdU(fu), encodes an in-frame fusion of MV-H, lacking its termination codon, with MV-F, lacking its signal sequence. Numbers in parentheses indicate the number of amino acids encoded by each DNA fragment.
FIG. 2.
FIG. 2.
Identification of the MV-H and MV-F proteins expressed in BHK-21 cells. Cell lysates were prepared from BHK-21 cells 48 h posttransfection with the different plasmid constructs. Cell lysates were separated on a 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel and transferred, and the immunoblot was probed with a mouse monoclonal anti-MV-H antibody (A) or with anti-MV-F antibody (B). Sizes are indicated in kilodaltons.
FIG. 3.
FIG. 3.
Syncytium formation in Vero cells transiently expressing MV-H and/or MV-F protein. Vero cells were transfected with the various plasmid constructs as indicated. Cells were photographed 48 h after transfection by phase-contrast microscopy. Magnification, ×100.
FIG. 4.
FIG. 4.
Induction of MV-specific IgG antibody in mice immunized i.m. with DNA vaccines encoding MV-H and/or -F. Groups of BALB/c mice (n = 10) were immunized i.m. on days 0 and 28 with 100 μg of the various plasmid constructs as depicted on the x axis. MV-specific IgG titers were measured by ELISA on days 0, 28, and 56. Bars show GM titers (EU/ml) ± the SD.
FIG. 5.
FIG. 5.
Serum PRN titers from mice i.m. immunized with DNA vaccines encoding MV-H and/or MV-F. Sera from the experiment outlined in Fig. 4 were assessed for their ability to neutralize MV replication in Vero cells using the plaque reduction neutralization assay. PRN titers were measured using sera prepared on days 0 and 56. Responses are expressed as GM titers (mIU/ml) ± SD.
FIG. 6.
FIG. 6.
Avidity of MV-specific serum IgG in mice immunized i.m. with DNA vaccines encoding MV-H and/or MV-F. Sera from day 56 of the experiment outlined in Fig. 4 were assessed for avidity. Bars show the percent binding after urea treatment ± SD from replicate measurements.
FIG. 7.
FIG. 7.
Measles virus-specific IFN-γ responses. On day 70, mice were sacrificed, their spleens were extracted and homogenized, and splenocytes were isolated. Single-cell suspensions were pooled within each group and restimulated in vitro for 48 h with 5 μg/ml MV lysate in an IFN-γ-specific ELISPOT assay. Results are expressed as the mean IFN-γ spot-forming cells (SFC) ± SD from triplicate wells/106 cells. IFN-γ spots in wells containing medium (controls) were subtracted from the spots counted in wells containing MV for all experimental groups.

Similar articles

Cited by

References

    1. Ad Hoc Group for the Study of Pertussis Vaccines. 1988. Placebo-controlled trial of two acellular pertussis vaccines in Sweden—protective efficacy and adverse events. Lancet i:955-960. - PubMed
    1. Albrecht, P., F. A. Ennis, E. J. Saltzman, and S. Krugman. 1977. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J. Pediatr. 91:715-718. - PubMed
    1. Alkhatib, G., J. Roder, C. Richardson, D. Briedis, R. Weinberg, D. Smith, J. Taylor, E. Paoletti, and S. H. Shen. 1994. Characterization of a cleavage mutant of the measles virus fusion protein defective in syncytium formation. J. Virol. 68:6770-6774. - PMC - PubMed
    1. Bosu, W. K., S. Odoom, P. Deiter, and M. Essel-Ahun. 2003. Epidemiology of measles in the central region of Ghana: a five-year case review in three district hospitals. East Afr. Med. J. 80:312-317. - PubMed
    1. Brodsky, A. L. 1972. Atypical measles. Severe illness in recipients of killed measles virus vaccine upon exposure to natural infection. JAMA 222:1415-1416. - PubMed

Publication types

MeSH terms